Submit Manuscript

Pharmacologia

Year: 2018 | Volume: 9 | Issue: 3 | Page No.: 129-136
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Article Trend

Total views 352

Search

Authors

Vikas Kumar

Vikas Kumar

Gulam Mohammad Husain

Gulam Mohammad Husain

Michael Nöldner

Egon Koch

Egon Koch

Keywords

Research Article

Adaptogenic Activity of WS® 1375, a Proprietary Dry Extract from Rhodiola rosea Roots and Rhizomes

Vikas Kumar Vikas Kumar's LiveDNA, Gulam Mohammad Husain Gulam Mohammad Husain's LiveDNA, Michael Nöldner and Egon Koch Egon Koch's LiveDNA
Background and Objectives: Rhodiola rosea L. has been widely used in folk medicine to improve endurance and work productivity and to relief symptoms of mental and physical stress. Thus, the present study was undertaken to evaluate the stress adaptogenic activity of a proprietary extract from roots and rhizomes of Rhodiola rosea L. (WS® 1375) and to elucidate its possible mechanism of action. Methodology: Rats were subjected to electrical foot shocks for 1 h by means of a grid floor in a standard conditioning chamber for 14 consecutive days to produce a state of chronic stress. WS® 1375 was orally administered in parallel at doses of 50, 150 or 450 mg kg–1 once daily 1 h before the induction of stress. Experiments were conducted 1 h after the last stress procedure on day 14. Gastric ulceration as well as weight of adrenal glands and spleens were observed to assess the intensity of stress. Stress induced behavioural perturbations were analyzed by behavioural despair test, learned helplessness test and inhibition of male sexual behaviour. Stress induced cognitive dysfunction was quantified using active and passive avoidance tests. Animals were sacrificed immediately after the last stress regimen and blood was withdrawn for corticosterone estimation. Brain samples of rats were collected and monoamine concentrations were measured. General neuropharmacological screening of WS® 1375 was also performed. Results: The investigations reveal that WS® 1375 has pronounced stress-preventive activity and significantly normalized the levels of brain nor-epinephrine, 5-HT and dopamine in a dose-dependent manner. Plasma corticosterone levels in animals treated with WS® 1375 (150 and 450 mg kg–1) were significantly lower when compared to vehicle-treated rats. While WS® 1375 exhibited CNS stimulant activity, it did not cause muscle ataxia and failed to significantly improve stress-induced cognitive impairment. Conclusion: Based on these observations, it is concluded that WS® 1375 has a great potential for therapeutic use as an adaptogen.
PDF Fulltext XML References Citation

Leave a Comment

Your email address will not be published. Required fields are marked *